Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females

Exclusion Criteria

• •Known or suspected pregnancy
• •A cervical cytology smear of Papanicolaou (Pap) class III or greater or a Bethesda System report of low grade squamous intraepithelial lesions (SIL) or greater
• •Smoking
• •Hypertension (blood pressure \>140 mm Hg systolic and/or \>90 mm Hg diastolic)
• •Diabetes Mellitus
• •History of headaches with focal neurological symptoms
• •Current or history of clinically significant depression in the last year
• •Acute or chronic hepatocellular disease with abnormal liver function
• •History of or existing venous and arterial thrombotic and thromboembolic disorder, vascular disease, cerebral vascular, or coronary artery disease
• •Chronic use of any medication that might interfere with the efficacy of hormone contraceptives (including barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate, and HIV protease inhibitors), OR use of these medications within the past 3 months prior to screening visit